US20220106326A1 - Crystalline forms of therapeutic compounds and uses thereof - Google Patents

Crystalline forms of therapeutic compounds and uses thereof Download PDF

Info

Publication number
US20220106326A1
US20220106326A1 US17/554,375 US202117554375A US2022106326A1 US 20220106326 A1 US20220106326 A1 US 20220106326A1 US 202117554375 A US202117554375 A US 202117554375A US 2022106326 A1 US2022106326 A1 US 2022106326A1
Authority
US
United States
Prior art keywords
crystalline form
disease
pharmaceutical composition
compound
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/554,375
Inventor
Minh Ngoc Nguyen
Winston Zapanta ONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kala Bio Inc
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Priority to US17/554,375 priority Critical patent/US20220106326A1/en
Assigned to KALA PHARMACEUTICALS, INC. reassignment KALA PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NGUYEN, MINH NGOC, ONG, Winston Zapanta
Publication of US20220106326A1 publication Critical patent/US20220106326A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • Growth factors play an important role in angiogenesis, lymphangiogenesis, and vasculogenesis. Growth factors regulate angiogenesis in a variety of processes including embryonic development, wound healing, and several aspects of female reproductive function. Undesirable or pathological angiogenesis is associated with diseases including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma, and hemangioma. Angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries.
  • Compound 1 may be useful for the treatment of the proliferative diseases associated with angiogenesis, such as angiogenic ocular diseases. This disclosure relates to crystalline forms of Compound 1.
  • Some embodiments include a process for preparing a crystalline form E described herein, comprising mixing Compound 1 and methanol.
  • Some embodiments include a pharmaceutical composition comprising a crystalline form disclosed herein.
  • Some embodiments include a method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form or a pharmaceutical composition.
  • FIG. 2 depicts an XRPD pattern of crystalline form C.
  • Crystalline form E may be a solvate, such as a methanol solvate.
  • crystalline form C may be prepared by stirring a slurry of amorphous Compound 1 or crystalline form E in ethyl acetate.
  • crystalline form C may be prepared by dissolving or dispersing Compound 1 in a suitable solvent, such as butanone or ethyl acetate.
  • Dry eye syndrome otherwise known as keratoconjunctivitis sicca (KCS), keratitis sicca, sicca syndrome, or xerophthalmia
  • KCS keratoconjunctivitis sicca
  • keratitis sicca keratitis sicca
  • sicca syndrome or xerophthalmia
  • DES Dry eye syndrome
  • ASD age-related macular degeneration
  • AMD age-related macular degeneration
  • CME cystoid macular edema
  • DME diabetic macular edema
  • CME is an ocular disease which affects the central retina or macula of the eye. When this condition is present, multiple cyst-like (cystoid) areas of fluid appear in the macula and cause retinal swelling or edema.
  • CME may accompany a variety of diseases such as retinal vein occlusion, uveitis, and/or diabetes.
  • CME commonly occurs after cataract surgery.
  • DME occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula. These leaks cause the macula to thicken and swell, progressively distorting acute vision. While the swelling may not lead to blindness, the effect can cause a severe loss in central vision.
  • Treatment or prevention of a disease may be accomplished by administering Compound 1 to a mammal, such as a human being, in need thereof.
  • compositions containing the particles described herein may be administered to a subject via any route known in the art. These include, but are not limited to, oral, sublingual, nasal, injection (e.g., intravenous, intradermal, subcutaneous, intramuscular), rectal, vaginal, intraarterial, intracisternally, intraperitoneal, intravitreal, periocular, topical (e.g., ocular or dermal, such as by powders, creams, ointments, or drops), buccal, and inhalational administration.
  • compositions described herein may be administered parenterally as injections (intravenous, intramuscular, or subcutaneous), drop infusion preparations, or suppositories.
  • the route of administration and the effective dosage to achieve the desired biological effect may be determined by the agent being administered, the target organ, the preparation being administered, time course of administration, disease being treated, intended use, etc.
  • an effective amount of Compound 1 in a crystalline form may vary from about 0.00001 mg/kg to about 100 mg/kg in one or more dose administrations for one or several days (depending on the mode of administration).
  • the effective amount per dose varies from about 0.00001 mg/kg to about 100 mg/kg, from about 0.0001 mg/kg to about 20 mg/kg, from about 0.001 mg/kg to about 5 mg/kg, from about 0.01 mg/kg to about 0.5 mg/kg, and from about 0.1 mg/kg to about 2 mg/kg, 0.5-5 mg/kg, 1-10 mg/kg, or any dose amount bounded by or between any of these values.
  • Compound 1 may be prepared by the method described in U.S. Pat. No. 9,458,169, which is hereby incorporated by reference for its description of the synthesis of Compound 1.
  • the XRPD pattern of crystalline form E is illustrated in FIG. 1 .
  • the peaks in degrees 2 ⁇ , the corresponding d-spacing values, and relative intensity (%) from the XRPD pattern of crystalline form E are listed in Table 2.
  • amorphous Compound 1 (30.7 mg) was added into a 4-mL scintillation vial with screw-top. To the vial was added a magnetic stir bar and ethyl acetate (500 ⁇ L). The vial was capped and the suspension in the vial was allowed to stir at ambient temperature (about 22° C.) and 300 RPM speed for two hours.

Abstract

Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application is a continuation of U.S. patent application Ser. No. 17/389,000 filed Jul. 29, 2021, which is a continuation of U.S. patent application Ser. No. 16/818,033 filed Mar. 13, 2020, which is a continuation of U.S. patent application Ser. No. 16/415,848 filed May 17, 2019, now U.S. Pat. No. 10,626,121, which is a divisional of U.S. patent application Ser. No. 15/694,252 filed Sep. 1, 2017, now U.S. Pat. No. 10,336,767, which claims the benefit of U.S. Provisional Patent Application 62/385,148, filed Sep. 8, 2016. The entire contents of each of these applications is incorporated by reference herein.
    • FIELD
  • This disclosure relates to crystalline forms of a therapeutic compound useful for treating diseases, including proliferative diseases and diseases associated with angiogenesis, such as cancer and macular degeneration.
    • BACKGROUND
  • Growth factors play an important role in angiogenesis, lymphangiogenesis, and vasculogenesis. Growth factors regulate angiogenesis in a variety of processes including embryonic development, wound healing, and several aspects of female reproductive function. Undesirable or pathological angiogenesis is associated with diseases including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma, and hemangioma. Angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the United States, for example, retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration are the principal causes of blindness in infants, working age adults, and the elderly, respectively. Efforts have been developed to inhibit angiogenesis in the treatment of these conditions.
  • Therefore, there is a need for new therapeutic compositions for the treatment of diseases associated with the aberrant signaling of growth factors and diseases associated with angiogenesis, such as cancer, macular degeneration, and diabetic retinopathy.
    • SUMMARY
  • Compound 1 may be useful for the treatment of the proliferative diseases associated with angiogenesis, such as angiogenic ocular diseases. This disclosure relates to crystalline forms of Compound 1.
  • Figure US20220106326A1-20220407-C00002
  • In some embodiments, the crystalline form has an X-ray powder diffraction (XRPD) pattern with a largest peak at about 10-11 degrees 2θ.
  • Some embodiments include a crystalline form of Compound 1 having an X-ray powder diffraction (XRPD) pattern with a largest peak at about 8-9 degrees 2θ.
  • Some embodiments include a process for preparing a crystalline form E described herein, comprising mixing Compound 1 and methanol.
  • Some embodiments include a process for preparing a crystalline form C described herein, comprising mixing Compound 1 and ethyl acetate.
  • Some embodiments include a pharmaceutical composition comprising a crystalline form disclosed herein.
  • Some embodiments include a kit comprising the crystalline form disclosed herein, or the pharmaceutical composition disclosed herein.
  • Some embodiments include a method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form or a pharmaceutical composition.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts the X-ray powder diffraction (XRPD) pattern of crystalline form E.
  • FIG. 2 depicts an XRPD pattern of crystalline form C.
    •  DETAILED DESCRIPTION
  • This description relates to crystal or crystalline forms of the compound 7-(3-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane, or a salt thereof, referred to herein as Compound 1 and shown below:
  • Figure US20220106326A1-20220407-C00003
  • In particular, two crystalline forms of Compound 1—crystalline form E and crystalline form C—are described herein.
  • Several X-ray powder diffraction (XRPD) patterns are depicted and described herein. As used herein, the “largest peak” refers to the peak in a diffraction pattern with the highest intensity. As used herein, the term “major intensity peak” includes any peak having an intensity that is in the top 20% of the peaks in a particular X-ray powder diffraction pattern.
    • Crystalline Form E
  • Crystalline form E has an XRPD pattern with a largest peak at about 10-11 degrees two theta (2θ). The diffraction pattern may also have a major intensity peak at about 15-16 degrees 2θ, about 18-19 degrees 2θ, about 23-23.5 degrees 2θ, and/or about 23.5-24 degrees 2θ, and may have other major intensity peaks.
  • Crystalline form E may be a solvate, such as a methanol solvate.
  • While there are many ways that crystalline form E may potentially be prepared, in some embodiments, crystalline form E may be prepared by stirring a slurry of amorphous Compound 1 in methanol.
    • Crystalline Form C
  • Crystalline form C has an XRPD pattern with a largest peak at about 8-9 degrees 2θ (e.g., about 8.65 degrees 2θ). The diffraction pattern may also have a major intensity peak at about 10.5-11.5 degrees 2θ (e.g., about 10.91 degrees 2θ), about 16-17 degrees 2θ (e.g., about 16.38 degrees 2θ), and/or about 18-19 degrees 2θ (e.g., about 18.54 degrees 2θ), about 19.5-20.5 degrees 2θ (e.g., about 20.02 degrees 2θ), about 21.5-22.5 degrees 2θ (e.g., about 22.17 degrees 2θ), and/or about 26-27 degrees 2θ (e.g., about 26.53 degrees 2θ), and may have other major intensity peaks. In some embodiments, crystalline form C has an XRPD pattern as shown in FIG. 2.
  • Crystalline form C also has a melting point of about 194-195° C.
  • Crystalline form C may be an anhydrate.
  • While there are many ways that crystalline form C may potentially be prepared, in some embodiments, crystalline form C may be prepared by stirring a slurry of amorphous Compound 1 or crystalline form E in ethyl acetate.
  • In some embodiments, crystalline form C may be prepared by dissolving or dispersing Compound 1 in a suitable solvent, such as butanone or ethyl acetate.
    • Methods of Treatment
  • Compound 1 may be used for treating and/or preventing a disease associated with aberrant signaling of a growth factor, such as vascular endothelial growth factor (VEGF). In some embodiments, Compound 1 in a crystalline form may be used to treat a disease associated with abnormal angiogenesis, such as cancer, benign neoplasm, atherosclerosis, hypertension, inflammatory disease, rheumatoid arthritis, macular degeneration (AMD), choroidal neovascularization, retinal neovascularization, and diabetic retinopathy. In certain embodiments, Compound 1 is used to treat cancer (e.g., an ocular cancer). In certain embodiments, Compound 1 is used to treat macular degeneration.
  • Compound 1 may also be used to treat or prevent a proliferative disease, such as cancer, ocular disease (e.g., retinopathy, age-related macular degeneration (AMD), corneal neovascularization, diabetic macular edema, retinal vein occlusion etc.).
  • The term “ocular disease” or “ocular disorder” includes any eye disease and/or disorder. For example, ocular diseases can be disorders of the eyelid, lacrimal system and orbit, disorders of conjunctiva, disorders of sclera, cornea, iris and ciliary body, disorders of choroid, disorders of retina, glaucoma, disorders of optic nerve and visual pathways, ocular neovascularization diseases or disorders, ocular inflammatory diseases, or disorders of ocular muscles. Additionally, ocular disease can also refer to discomfort following injury, surgery, or laser treatment. Diseases and disorders of the eye or ocular diseases include, but are not limited to, retinopathy, diabetic retinopathy, retinal vein occlusion, macular degeneration, age-related macular degeneration, dry eye syndrome, blepharitis, inflammatory meibomian gland disease, uveitis, allergic conjunctivitis, glaucoma, macular edema, diabetic macular edema, cystoid macular edema, and rosacea (of the eye). Dry eye syndrome (DES), otherwise known as keratoconjunctivitis sicca (KCS), keratitis sicca, sicca syndrome, or xerophthalmia, is an eye disease caused by decreased tear production or increased tear film evaporation commonly found in humans and some animals.
  • The term “age-related macular degeneration” or “AMD” includes an ocular disease which usually affects older adults and results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. It occurs in “dry” and “wet” forms. It is a major cause of blindness and visual impairment in older adults (>50 years).
  • Macular degeneration can make it difficult or impossible to read or recognize faces, although enough peripheral vision remains to allow other activities of daily life. The macula is the central area of the retina, which provides the most detailed central vision. In the dry (nonexudative) form, cellular debris called drusen accumulate between the retina and the choroid, and the retina can become detached. In the wet (exudative) form, which is more severe, blood vessels grow up from the choroid behind the retina, and the retina can also become detached. It can be treated with laser coagulation, and with medication that stops and sometimes reverses the growth of blood vessels. Macular degeneration includes some macular dystrophies affecting younger subjects as well as age-related macular degeneration (AMD or ARMD), which is more commonly known. AMD begins with characteristic yellow deposits (drusen) in the macula, between the retinal pigment epithelium and the underlying choroid. Most patients with these early changes (referred to as age-related maculopathy) have good vision. Patients with drusen can go on to develop advanced AMD. The risk is considerably higher when the drusen are large and numerous and associated with disturbance in the pigmented cell layer under the macula. Recent research suggests that large and soft drusen are related to elevated cholesterol deposits and may respond to cholesterol-lowering agents.
  • The term “macular edema” refers to the ocular diseases cystoid macular edema (CME) or diabetic macular edema (DME). CME is an ocular disease which affects the central retina or macula of the eye. When this condition is present, multiple cyst-like (cystoid) areas of fluid appear in the macula and cause retinal swelling or edema. CME may accompany a variety of diseases such as retinal vein occlusion, uveitis, and/or diabetes. CME commonly occurs after cataract surgery. DME occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula. These leaks cause the macula to thicken and swell, progressively distorting acute vision. While the swelling may not lead to blindness, the effect can cause a severe loss in central vision.
  • The term “glaucoma” refers to an ocular disease in which the optic nerve is damaged in a characteristic pattern. This can permanently damage vision in the affected eye and lead to blindness if left untreated. It is normally associated with increased fluid pressure in the eye (aqueous humor). The term ocular hypertension is used for patients with consistently raised intraocular pressure (IOP) without any associated optic nerve damage. Conversely, the term normal tension or low tension glaucoma is used for those with optic nerve damage and associated visual field loss but normal or low IOP. The nerve damage involves loss of retinal ganglion cells in a characteristic pattern. There are many different subtypes of glaucoma, but they can all be considered to be a type of optic neuropathy. Raised intraocular pressure (e.g., above 21 mmHg or 2.8 kPa) is the most important and only modifiable risk factor for glaucoma. However, some may have high eye pressure for years and never develop damage, while others can develop nerve damage at a relatively low pressure. Untreated glaucoma can lead to permanent damage of the optic nerve and resultant visual field loss, which over time can progress to blindness.
  • The term “uveitis” refers to an inflammatory disease of the uvea, the vascular layer of the eye sandwiched between the retina and the white of the eye (sclera). The uvea extends toward the front of the eye and consists of the iris, choroid layer and ciliary body. Uveitis includes anterior uveitis, intermediate uveitis, and posterior uveitis. A most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis may also occur at the posterior segment of the eye (e.g., at the choroid). Inflammation of the uvea can be recurring and can cause serious problems such as blindness if left untreated (accounts for 10% of blindness globally). Early diagnosis and treatment are important to prevent the complications of uveitis.
  • The term “dry eye” or “dry eyes” includes an ocular disease in which there is insufficient tears to lubricate and nourish the eye. Tears are necessary for maintaining the health of the front surface of the eye and for providing clear vision. Patients with dry eyes either do not produce enough tears or have a poor quality of tears. Dry eye is a common and often chronic problem, particularly in older adults. With each blink of the eyelids, tears are spread across the front surface of the eye, known as the cornea. Tears provide lubrication, reduce the risk of eye infection, wash away foreign matter in the eye, and keep the surface of the eyes smooth and clear. Excess tears in the eyes flow into small drainage ducts, in the inner corners of the eyelids, which drain in the back of the nose. Tears are produced by several glands (e.g., lacrimal gland) in and around the eyelids. Tear production tends to diminish with age, with various medical conditions, or as a side effect of certain medicines. Environmental conditions such as wind and dry climates can also affect tear volume by increasing tear evaporation. When the normal amount of tear production decreases or tears evaporate too quickly from the eyes, symptoms of dry eye can develop. The most common form of dry eyes is due to an inadequate amount of the water layer of tears. This condition, called keratoconjunctivitis sicca (KCS), is also referred to as “dry eye syndrome.”
  • The term “diabetic retinopathy” includes retinopathy (i.e., a disease of the retina) caused by complications of diabetes, which can eventually lead to blindness. Diabetic retinopathy may cause no symptoms, mild vision problems, or even blindness. Diabetic retinopathy is the result of microvascular retinal changes. Hyperglycemia-induced intramural pericyte death and thickening of the basement membrane lead to incompetence of the vascular walls. These damages change the formation of the blood-retinal barrier and also make the retinal blood vessels become more permeable. The pericyte death is caused when hyperglycemia persistently activates protein kinase C-δ (PKC-δ, encoded by Prkcd) and p38 mitogen-activated protein kinase (MAPK) to increase the expression of a previously unknown target of PKC-δ signaling, Src homology-2 domain-containing phosphatase-1 (SHP-1), a protein tyrosine phosphatase. This signaling cascade leads to PDGF receptor-dephosphorylation and a reduction in downstream signaling from this receptor, resulting in pericyte apoptosis. Small blood vessels, such as those in the eye, are especially vulnerable to poor control over blood sugar. An overaccumulation of glucose and/or fructose damages the tiny blood vessels in the retina. During the initial stage, called “nonproliferative diabetic retinopathy” (NPDR), most patients do not notice any change in their vision. Early changes that are reversible and do not threaten central vision are sometimes termed simplex retinopathy or background retinopathy. As the disease progresses, severe nonproliferative diabetic retinopathy enters an advanced, “proliferative diabetic retinopathy” (PDR) stage when blood vessels proliferate. The lack of oxygen in the retina causes fragile, new, blood vessels to grow along the retina and in the clear, gel-like vitreous humor that fills the inside of the eye, which may result in bleeding, cloudy vision, retina damage, or tractional retinal detachment.
  • Treatment or prevention of a disease may be accomplished by administering Compound 1 to a mammal, such as a human being, in need thereof.
    • Pharmaceutical Compositions
  • A crystalline form of Compound 1, such as a crystalline form E or crystalline form C, hereafter referred to as a “crystalline form,” may be present in a pharmaceutical composition that may further comprise a pharmaceutically acceptable excipient.
  • A crystalline form of Compound 1 may be intended for delivery in a subject.
    • Excipients
  • A pharmaceutically acceptable excipient or pharmaceutically acceptable carrier may include a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any suitable type. Any pharmaceutically acceptable excipient may be used herein. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as TWEEN 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. As would be appreciated by one of skill in this art, the excipients may be chosen based on the route of administration as described below, the pharmaceutical agent being delivered, time course of delivery of the agent, etc.
  • Non-limiting examples of polymers which can be included in the disclosed pharmaceutical compositions include polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyeneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates. Non-limiting examples of specific polymers include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacrylate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), poly(ethylene glycol), poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose, polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PM MA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) (jointly referred to herein as “polyacrylic acids”), and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate), polyoxymethylene, poloxamers, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), and trimethylene carbonate.
    • Route of Administration
  • Pharmaceutical compositions containing the particles described herein may be administered to a subject via any route known in the art. These include, but are not limited to, oral, sublingual, nasal, injection (e.g., intravenous, intradermal, subcutaneous, intramuscular), rectal, vaginal, intraarterial, intracisternally, intraperitoneal, intravitreal, periocular, topical (e.g., ocular or dermal, such as by powders, creams, ointments, or drops), buccal, and inhalational administration. In some embodiments, compositions described herein may be administered parenterally as injections (intravenous, intramuscular, or subcutaneous), drop infusion preparations, or suppositories. The route of administration and the effective dosage to achieve the desired biological effect may be determined by the agent being administered, the target organ, the preparation being administered, time course of administration, disease being treated, intended use, etc.
  • Moreover, the pharmaceutical compositions may be administered parenterally as injections (intravenous, intramuscular, or subcutaneous), drop infusion preparations, or suppositories. For ophthalmic applications, the pharmaceutical compositions may be administered by injection (e.g., intraocular, conjunctival, subconjunctival, intrastromal, intravitreal, or intracameral), or by the local or ophthalmic mucous membrane route, the pharmaceutical compositions may be administered topically, such as solutions, suspensions (e.g., eye drops), gels, or ointments.
  • In some embodiments, an effective amount of Compound 1 in a crystalline form may vary from about 0.00001 mg/kg to about 100 mg/kg in one or more dose administrations for one or several days (depending on the mode of administration). In certain embodiments, the effective amount per dose varies from about 0.00001 mg/kg to about 100 mg/kg, from about 0.0001 mg/kg to about 20 mg/kg, from about 0.001 mg/kg to about 5 mg/kg, from about 0.01 mg/kg to about 0.5 mg/kg, and from about 0.1 mg/kg to about 2 mg/kg, 0.5-5 mg/kg, 1-10 mg/kg, or any dose amount bounded by or between any of these values.
    • EXAMPLES Example 1. Synthesis of Compound 1
  • Compound 1 may be prepared by the method described in U.S. Pat. No. 9,458,169, which is hereby incorporated by reference for its description of the synthesis of Compound 1.
    • Example 2. Preparation of amorphous Compound 1
  • The synthesized Compound 1 (6.25 g) was suspended in water (300 mL). Hydrochloric acid (1M, 20 mL) was added. All material dissolved to form a light yellow solution. The solution was filtered through a disk filter (1 μm) and placed under high vacuum with magnetic stirring for 10 minutes. While stirring a saturated sodium bicarbonate (300 mL) was added over 10 minutes. The high vacuum was applied for additional 10 minutes and the solution was stirred for 30 minutes under normal pressure. The solid precipitate was filtered off on a sintered glass funnel (F porosity). The solid was washed with water (300 mL) and dried by passage of vacuum for 1 hour. The solid was further dried under high vacuum overnight. The material obtained was a white amorphous solid (5.45 g).
    • Example 3: Preparation of Crystalline Form E
  • Crystalline form E was prepared by stirring a slurry of amorphous Compound 1 in methanol.
  • In one instance, amorphous Compound 1 (30.8 mg) was added into a 4-mL scintillation vial with screw-top. To the vial was added a magnetic stir bar and methanol (500 μL). The vial was capped and the suspension in the vial was allowed to stir at ambient temperature (about 22° C.) with 300 RPM speed for two hours.
  • The solid material was collected by centrifuge filtration and the filtrate was discarded. The centrifuge filter tube was then lightly covered and dried under high vacuum for approximately 17 hours. The recovered dry solid (26.7 mg) was analyzed by X-ray powder diffraction (XRPD), which showed a unique powder pattern that was assigned as crystalline form E. This experiment was successfully reproduced three times as indicated in Table 1.
  • TABLE 1
    Summary of conversion to crystalline
    form E from amorphous Compound 1.
    Initial Crystalline
    Amorphous Volume of Concen- Form E Recovery
    Experi- initially methanol tration Recovered Yield by
    ment used (mg) added (uL) (mg/mL) (mg) mass
    1 30.8 0.5 61.6 26.7 92.2%
    2 29.6 0.5 59.2 25.5 91.6%
    3 29.7 0.5 59.4 26.6 95.2%
    • Properties of Crystalline Form E
  • The XRPD pattern of crystalline form E is illustrated in FIG. 1. The peaks in degrees 2θ, the corresponding d-spacing values, and relative intensity (%) from the XRPD pattern of crystalline form E are listed in Table 2.
  • TABLE 2
    XRPD peak listing of crystalline form E.
    Position ± d-spacing ± Relative
    Peak No. 0.2° [2θ] 0.2 [Å] Intensity [%]
    1 8.55 10.33 12.85
    2 8.95 9.87 8.72
    3 9.43 9.37 6.27
    4 10.22 8.65 100.00
    5 14.19 6.23 14.09
    6 14.65 6.04 9.27
    7 14.90 5.94 28.70
    8 15.38 5.76 40.99
    9 15.86 5.58 52.79
    10 16.50 5.37 32.26
    11 17.07 5.19 3.65
    12 17.69 5.01 16.53
    13 18.90 4.69 45.03
    14 19.43 4.57 35.00
    15 20.33 4.36 12.97
    16 20.57 4.31 39.09
    17 21.36 4.16 5.34
    18 22.36 3.97 35.40
    19 23.24 3.82 11.49
    20 23.46 3.79 67.26
    21 23.75 3.74 45.38
    22 25.63 3.47 26.16
    23 26.76 3.33 8.83
    24 28.52 3.13 22.86
    25 28.93 3.08 10.61
    26 29.56 3.02 5.47
    27 34.19 2.62 3.74
  • Thermogravimetric Analysis (TGA) was found to exhibit a mass loss of 8.88%. Since solution 1H NMR confirmed the presence of methanol in neat crystalline form E, the TGA data suggests that the mass loss is possibly due to loss of methanol.
    • Example 4. Preparation of Crystalline Form C
  • Crystalline form C was prepared by stirring a slurry of amorphous of Compound 1 in ethyl acetate.
  • In one instance, amorphous Compound 1 (30.7 mg) was added into a 4-mL scintillation vial with screw-top. To the vial was added a magnetic stir bar and ethyl acetate (500 μL). The vial was capped and the suspension in the vial was allowed to stir at ambient temperature (about 22° C.) and 300 RPM speed for two hours.
  • The solid material was collected by centrifuge filtration and the filtrate was discarded. The centrifuge filter tube was then lightly covered and dried under high vacuum for approximately 17 hours. The recovered dry solid (25.8 mg) was analyzed by XRPD, which showed a unique powder pattern that was assigned as crystalline form C. This experiment was successfully reproduced three times as indicated in Table 3.
  • TABLE 3
    Summary of conversion to crystalline
    form C from amorphous Compound 1.
    Initial Crystalline
    Amorphous Volume of Concen- Form C Recovery
    Experi- initially ethyl acetate tration Recovered Yield by
    ment used (mg) added (uL) (mg/mL) (mg) mass
    1 30.7 0.5 61.4 25.8 84.0%
    2 30.4 0.5 60.8 26.6 87.5%
    3 30.5 0.5 61.0 27.4 89.8%
  • Crystalline form C was also prepared by stirring a slurry of crystalline form E of Compound 1 in ethyl acetate.
  • In one instance, crystalline form E of Compound 1 (29.9 mg) was added into a 4-mL scintillation vial with screw-top. To the vial was added a magnetic stir bar and ethyl acetate (300 μL). The vial was capped and placed onto a hot plate equipped with a magnetic stirring control that was preheated to 40° C. The suspension in the vial was allowed to stir at 40° C. and 300 RPM for two hours.
  • The solid material was collected by centrifuge filtration and the filtrate was discarded. The centrifuge filter tube was then lightly covered and dried under high vacuum for approximately 17 hours. The recovered dry solid (24.3 mg) was analyzed by XRPD, which showed a unique powder pattern that was assigned as crystalline form C. This experiment was successfully reproduced three times as indicated in Table 4.
  • TABLE 4
    Summary of conversion to crystalline
    form C from crystalline form E.
    Crystalline Initial Crystalline
    form E Volume of Concen- Form C Recovery
    Experi- initially ethyl acetate tration Recovered Yield by
    ment used (mg) added (μL) (mg/mL) (mg) mass
    1 29.9 300 100 24.3 86.4%
    2 30.1 300 100 24.8 87.6%
    3 31.8 300 106 26.4 88.3%
    • Properties of Crystalline Form C
  • The XRPD pattern of crystalline form C is illustrated in FIG. 2. The peaks in degrees two-theta, the corresponding d-spacing values, and relative intensity in the XRPD pattern of form C are listed in Table 5.
  • TABLE 5
    XRPD peak listing of crystalline form C.
    Position ± d-spacing ± Relative
    Peak No. 0.2° [2θ] 0.2 [Å] Intensity [%]
    1 6.74 13.11 2.0
    2 8.65 10.21 100.0
    3 9.92 8.91 4.0
    4 10.91 8.10 31.9
    5 13.19 6.71 3.1
    6 13.78 6.42 2.0
    7 14.38 6.15 9.6
    8 15.95 5.55 4.6
    9 16.15 5.48 3.3
    10 16.38 5.41 12.7
    11 17.36 5.10 1.8
    12 18.54 4.78 31.9
    13 18.76 4.73 10.1
    14 19.08 4.65 1.5
    15 19.77 4.49 8.3
    16 20.02 4.43 21.5
    17 20.77 4.27 11.6
    18 21.72 4.09 3.6
    19 22.17 4.01 18.8
    20 23.02 3.86 10.3
    21 24.74 3.60 1.8
    22 25.72 3.46 1.2
    23 25.92 3.44 6.0
    24 26.21 3.40 4.9
    25 26.53 3.36 13.5
    26 27.21 3.28 0.5
    27 27.56 3.23 7.0
    28 28.81 3.10 3.1
    29 29.61 3.01 1.8
    30 32.64 2.74 0.4
    31 33.08 2.71 3.0
    32 33.95 2.64 0.5
    33 34.30 2.61 0.8
    34 34.92 2.57 1.9
    35 36.58 2.45 1.5
    36 38.95 2.31 0.9
  • TGA analysis was found to exhibit a mass loss of 0.16% possibly due to loss of residual surface moisture or residual ethyl acetate, thereby confirming that crystalline form C is anhydrous.
  • The foregoing description details specific methods and compositions that can be employed to make and use the compounds described herein, and represents the best mode contemplated. However, it is apparent for one of ordinary skill in the art that other compounds with the desired pharmacological properties can be prepared in an analogous manner, and that the disclosed compounds can also be obtained from different starting compounds via different chemical reactions. Similarly, different pharmaceutical compositions may be prepared and used with substantially the same result. Thus, the foregoing description should not be construed as limiting the scope of the claims.
  • Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
  • The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
  • Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
  • Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
  • Specific embodiments disclosed herein may be further limited in the claims using consisting of or consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.
  • Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.
  • In closing, it is to be understood that the embodiments disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

Claims (16)

What is claimed is:
1. A crystalline form of Compound 1:
Figure US20220106326A1-20220407-C00004
wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern with a largest peak at about 8-9 degrees 2θ.
2. The compound of claim 1 wherein the crystalline form is an anhydrate.
3. A process for preparing a crystalline form of either of claim 1 or claim 2, comprising mixing Compound 1 and ethyl acetate.
4. A pharmaceutical composition comprising the crystalline form of either of claim 1 or claim 2 and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is suitable for topical administration.
6. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is suitable for injection.
7. The pharmaceutical composition of any one of claim 4, 5 or 6, wherein the pharmaceutical composition is suitable for delivery to the eye.
8. A kit comprising the crystalline form of any one of claim 1, 2, or 3, or the pharmaceutical composition of any one of claim 4, 5, 6, or 7.
9. A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form of any one of claim 1 or 2 or the pharmaceutical composition of any one of claim 4, 5, 6, or 7.
10. The method of claim 9, wherein the disease is a proliferative disease.
11. The method of claim 8, wherein the disease is cancer.
12. The method of claim 9, wherein the disease is an ocular disease.
13. The method of claim 9, wherein the disease is retinopathy.
14. The method of claim 9, wherein the disease is age-related macular degeneration (AMD).
15. The method of claim 9, wherein the disease is corneal neovascularization.
16. A method of inhibiting growth factor signaling comprising administering to a subject a therapeutically effective amount of the crystalline form of any one of claim 1 or 2 or the pharmaceutical composition of any one of claim 4, 5, 6, or 7.
US17/554,375 2016-09-08 2021-12-17 Crystalline forms of therapeutic compounds and uses thereof Abandoned US20220106326A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/554,375 US20220106326A1 (en) 2016-09-08 2021-12-17 Crystalline forms of therapeutic compounds and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662385148P 2016-09-08 2016-09-08
US15/694,252 US10336767B2 (en) 2016-09-08 2017-09-01 Crystalline forms of therapeutic compounds and uses thereof
US16/415,848 US10626121B2 (en) 2016-09-08 2019-05-17 Crystalline forms of therapeutic compounds and uses thereof
US16/818,033 US11104685B2 (en) 2016-09-08 2020-03-13 Crystalline forms of therapeutic compounds and uses thereof
US17/389,000 US20210355136A1 (en) 2016-09-08 2021-07-29 Crystalline forms of therapeutic compounds and uses thereof
US17/554,375 US20220106326A1 (en) 2016-09-08 2021-12-17 Crystalline forms of therapeutic compounds and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/389,000 Continuation US20210355136A1 (en) 2016-09-08 2021-07-29 Crystalline forms of therapeutic compounds and uses thereof

Publications (1)

Publication Number Publication Date
US20220106326A1 true US20220106326A1 (en) 2022-04-07

Family

ID=61281989

Family Applications (5)

Application Number Title Priority Date Filing Date
US15/694,252 Active US10336767B2 (en) 2016-09-08 2017-09-01 Crystalline forms of therapeutic compounds and uses thereof
US16/415,848 Active US10626121B2 (en) 2016-09-08 2019-05-17 Crystalline forms of therapeutic compounds and uses thereof
US16/818,033 Active US11104685B2 (en) 2016-09-08 2020-03-13 Crystalline forms of therapeutic compounds and uses thereof
US17/389,000 Abandoned US20210355136A1 (en) 2016-09-08 2021-07-29 Crystalline forms of therapeutic compounds and uses thereof
US17/554,375 Abandoned US20220106326A1 (en) 2016-09-08 2021-12-17 Crystalline forms of therapeutic compounds and uses thereof

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US15/694,252 Active US10336767B2 (en) 2016-09-08 2017-09-01 Crystalline forms of therapeutic compounds and uses thereof
US16/415,848 Active US10626121B2 (en) 2016-09-08 2019-05-17 Crystalline forms of therapeutic compounds and uses thereof
US16/818,033 Active US11104685B2 (en) 2016-09-08 2020-03-13 Crystalline forms of therapeutic compounds and uses thereof
US17/389,000 Abandoned US20210355136A1 (en) 2016-09-08 2021-07-29 Crystalline forms of therapeutic compounds and uses thereof

Country Status (10)

Country Link
US (5) US10336767B2 (en)
EP (1) EP3509421A4 (en)
JP (1) JP2019533641A (en)
KR (1) KR20190051010A (en)
CN (1) CN109688818A (en)
AU (2) AU2017324251A1 (en)
BR (1) BR112019004463A2 (en)
CA (1) CA3036065A1 (en)
MX (1) MX2019002629A (en)
WO (1) WO2018048746A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509421A4 (en) * 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336767B2 (en) * 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
CA1325382C (en) 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5442039A (en) 1989-07-17 1995-08-15 The Dow Chemical Company Mesogenic polycyanates and thermosets thereof
US5190956A (en) 1990-09-07 1993-03-02 Schering Corporation Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections
CA2113115A1 (en) 1991-07-29 1993-02-18 Vlad E. Gregor Quinazoline derivatives as acetylcholinesterase inhibitors
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5364884A (en) 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
WO1995003356A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
WO1995022318A1 (en) 1994-02-17 1995-08-24 Pankaj Modi Drugs, vaccines and hormones in polylactide coated microspheres
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6106819A (en) 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
US6517860B1 (en) 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
AU744089C (en) 1997-01-06 2003-07-31 Cerus Corporation Frangible compounds for pathogen inactivation
JP3884484B2 (en) 1997-01-16 2007-02-21 マサチューセッツ インスティチュート オブ テクノロジー Preparation of particles for inhalation
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
FR2772763B1 (en) 1997-12-24 2004-01-23 Sod Conseils Rech Applic NOVEL TETRACYCLIC CAMPTOTHECIN ANALOGS, PROCESSES FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
IL142121A0 (en) 1998-09-29 2002-03-10 American Cyanamid Co Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
ATE294796T1 (en) 1998-10-08 2005-05-15 Astrazeneca Ab QUINAZOLINE DERIVATIVES
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
CN1338924A (en) 1999-01-08 2002-03-06 艾米斯菲尔技术有限公司 Polymeric delivery agents and delivery agent compounds
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
DE60013773T2 (en) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methods for the preparation of therapeutic calcium phosphate particles
HU230000B1 (en) 1999-02-10 2015-04-28 Astrazeneca Ab Intermediates for the preparation of angiogenesis inhibitory quinazoline derivatives
CN1341104A (en) 1999-02-27 2002-03-20 贝林格尔英格海姆法玛公司 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19911509A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AR035851A1 (en) 2000-03-28 2004-07-21 Wyeth Corp 3-CIANOQUINOLINS, 3-CIANO-1,6-NAFTIRIDINES AND 3-CIANO-1,7-NAFTIRIDINS AS INHIBITORS OF PROTEIN KINASES
JP2004500415A (en) 2000-03-30 2004-01-08 ザ　ペン　ステート　リサーチ　ファウンデイション New compounds to enhance chemotherapy
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
CA2415469A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
DE10042059A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
BRPI0113757B8 (en) 2000-09-11 2017-11-07 Chiron Corp quinolinone derivatives as tyrosine kinase inhibitors
FR2814167B1 (en) 2000-09-15 2002-11-08 Aventis Pharma Sa PREPARATION OF CAMPTOTHECIN AND ITS DERIVATIVES
WO2002060868A2 (en) 2000-10-25 2002-08-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2004534721A (en) 2000-10-31 2004-11-18 ピーアール ファーマシューティカルズ，インク． Methods and compositions for enhanced delivery of bioactive molecules
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB2370839A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
ATE325795T1 (en) 2001-03-23 2006-06-15 Bayer Corp RHO KINASE INHIBITORS
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
SE0101675D0 (en) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
DE10128110A1 (en) 2001-06-11 2003-01-02 Univ Hannover Compounds for attachment to nucleic acids
PE20030008A1 (en) 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc Novel quinolines and uses thereof
EP1406593B1 (en) 2001-06-22 2010-08-25 Johns Hopkins University School of Medicine Biodegradable polymer compositions, compositions and uses related thereto
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
AU2002365611A1 (en) 2001-12-05 2003-06-17 F. Hoffmann - La Roche Ag Inflammation modulators
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk Novel phenylalanine derivative
WO2003051906A2 (en) 2001-12-14 2003-06-26 Smithkline Beecham Corporation Compounds and methods
AU2003202094B2 (en) 2002-02-01 2009-10-08 Astrazeneca Ab Quinazoline compounds
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2006220411B2 (en) 2002-03-20 2008-06-26 Alkermes, Inc. Inhalable Sustained Therapeutic Formulations
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2003101491A1 (en) 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1815868A3 (en) 2002-09-26 2007-08-15 Astellas Pharma Inc. Drug absorptivity improving agent
CA2513493A1 (en) 2002-11-08 2004-05-27 Schering Corporation Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP4611745B2 (en) 2002-11-20 2011-01-12 アレイ バイオファーマ、インコーポレイテッド Cyanoguanidine and cyanoamidine as ErbB2 and EGFR inhibitors
KR20050087863A (en) 2002-12-24 2005-08-31 아스트라제네카 아베 Quinazoline compounds
ES2314271T3 (en) 2002-12-24 2009-03-16 Astrazeneca Ab THERAPEUTIC QUINAZOLINE DERIVATIVES.
ATE438644T1 (en) 2002-12-24 2009-08-15 Astrazeneca Ab CHINAZOLINE DERIVATIVES
JPWO2004060400A1 (en) 2003-01-06 2006-05-11 那波　宏之 Antipsychotic drug targeting epidermal growth factor receptor
US20050266090A1 (en) 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
WO2005044224A2 (en) 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
US7842232B2 (en) 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050009809A1 (en) 2003-07-11 2005-01-13 Matthias Gerlach Acridine derivatives and their use as medicaments
DE10331500A1 (en) 2003-07-11 2005-02-24 Zentaris Gmbh Novel acridine derivatives and their use as pharmaceuticals
US20050124562A1 (en) 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
WO2005035521A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Substituted quinolines as mcr modulators
WO2005046590A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Methods for synthesizing quinolinone compounds
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2007518823A (en) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド Quinoline, quinazoline, pyridine, and pyrimidine compounds and their use in the treatment of inflammation, angiogenesis, and cancer
TW200536851A (en) 2004-01-23 2005-11-16 Amgen Inc Compounds and methods of use
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
SE0400284D0 (en) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
JP5019884B2 (en) 2004-02-20 2012-09-05 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Regulation of inflammatory and metastatic processes
JP2007526322A (en) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー Nanocell drug delivery system
CA2560824A1 (en) 2004-03-25 2005-10-13 Bausch & Lomb Incorporated Use of loteprednol etabonate for the treatment of dry eye
WO2005097137A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
AU2005244745B2 (en) 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
ES2246694B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
JP2007536310A (en) 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト Combination comprising S1P receptor agonist and JAK3 kinase inhibitor
US20100226931A1 (en) 2004-06-24 2010-09-09 Nicholas Valiante Compounds for immunopotentiation
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
CN101031551A (en) 2004-07-06 2007-09-05 安吉永生物制药公司 Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd Joint use of sulfonamide based compound with angiogenesis inhibitor
US8653055B2 (en) 2004-09-15 2014-02-18 Teva Animal Health, Inc. Corticosteroid having low systemic absorption
MX2007003506A (en) 2004-09-27 2007-05-10 Aztrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib.
US7906136B2 (en) 2004-10-01 2011-03-15 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
US20090036474A1 (en) 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
MX2007006230A (en) 2004-11-30 2007-07-25 Amgen Inc Quinolines and quinazoline analogs and their use as medicaments for treating cancer.
US8354476B2 (en) 2004-12-10 2013-01-15 Kala Pharmaceuticals, Inc. Functionalized poly(ether-anhydride) block copolymers
JP2008530239A (en) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Anti-angiogenic agents containing aldesleukin
DE102005009705A1 (en) 2005-03-03 2006-09-07 Universität des Saarlandes Use of naphthalene derivatives for the treatment of hyperaldosteronism, heart failure, myocardial fibrosis, hypercortisolism and diabetes mellitus
WO2006092430A1 (en) 2005-03-03 2006-09-08 Universität des Saarlandes Selective inhibitors of human corticosteroid synthases
DE102005011786A1 (en) 2005-03-11 2006-09-14 Pharmasol Gmbh Process for preparing ultrafine submicron suspensions
US8048889B2 (en) 2005-03-29 2011-11-01 Xtl Biopharmaceuticals Ltd. 3,4-disubstituted coumarin and quinolone compounds
CA2603345C (en) 2005-04-01 2017-05-02 Insa Rouen New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US20060257487A1 (en) 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
CA2608540A1 (en) 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
WO2006127205A2 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
CN101203494A (en) 2005-05-25 2008-06-18 惠氏公司 Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
CN1313449C (en) 2005-07-14 2007-05-02 沈阳中海生物技术开发有限公司 New quinazoline hind derivative, medicinal composition containing same and their use
US20100105031A1 (en) 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
FR2889527A1 (en) 2005-08-05 2007-02-09 Servier Lab NOVEL CAMPTOTHECIN ANALOG COMPOUNDS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP4792262B2 (en) 2005-09-09 2011-10-12 富士フイルム株式会社 Organic electroluminescent device and complex compound
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007034479A2 (en) 2005-09-20 2007-03-29 Yissum Research Development Company Nanoparticles for targeted delivery of active agents
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN1955183B (en) 2005-10-28 2011-04-20 中国医学科学院药物研究所 20-bit esterified camptothecine derivate, its preparation method and drug composite and use
EP1785420A1 (en) 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
US20070149523A1 (en) 2005-11-14 2007-06-28 Jan Ehlert Thiazole Analogues and Uses Thereof
PT1962808E (en) 2005-12-14 2010-10-29 Hoffmann La Roche Hcv prodrug formulation
WO2007076448A2 (en) 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US20070213319A1 (en) 2006-01-11 2007-09-13 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
US20070196860A1 (en) 2006-01-18 2007-08-23 Invitrogen Corporation Methods for Measuring Real Time Kinase Activity
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP2010677A4 (en) 2006-02-24 2010-04-14 Investigen Inc Methods and compositions for detecting polynucleotides
WO2008041960A2 (en) 2006-02-24 2008-04-10 Investigen, Inc. Methods and compositions for detecting polynucleotides
WO2007104696A1 (en) 2006-03-15 2007-09-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antimalarial agents having polyaromatic structure
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
JP5313867B2 (en) 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド Camptothecin-cell penetrating peptide complex and pharmaceutical composition containing the same
KR20080112380A (en) 2006-04-14 2008-12-24 아스트라제네카 아베 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US20100003291A1 (en) 2006-05-15 2010-01-07 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
EP2028938A4 (en) 2006-05-15 2010-07-07 Xtl Biopharmaceuticals Ltd 3,4-disubstituted coumarin and quinolone compounds
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
EP2032538A2 (en) 2006-06-08 2009-03-11 Array Biopharma, Inc. Quinoline compounds and methods of use
EP2044939A1 (en) 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
CN104606194A (en) 2006-07-07 2015-05-13 S·P·戈瓦克 Bicyclic heteroaryl inhibitors of pde4
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
ES2360538T3 (en) 2006-09-08 2011-06-06 Johns Hopkins University COMPOSITIONS TO INCREASE TRANSPORTATION THROUGH MOCO.
AU2007296745B2 (en) 2006-09-11 2011-12-01 Curis, Inc. Quinazoline based EGFR inhibitors
US8821943B2 (en) 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US20080096193A1 (en) 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
US7851623B2 (en) 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
CA2672440A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
CN100540552C (en) 2007-02-01 2009-09-16 中国药科大学 3-cyano-quinoline derivatives, its preparation method and medicinal use thereof
CN100540551C (en) 2007-02-01 2009-09-16 中国药科大学 Quinoline, its preparation method and medicinal use thereof
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
JP2008214323A (en) 2007-03-08 2008-09-18 Kyowa Hakko Kogyo Co Ltd Treating and/or prophylactic agent of skin disease
NZ598251A (en) 2007-03-14 2013-06-28 Exelixis Patent Co Llc 2-Arylamino-pyridopyrimidines and their uses, particularly in the treatment of cancer
WO2008113161A1 (en) 2007-03-19 2008-09-25 Ulysses Pharmaceutical Products Inc. Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same
DE102007015169A1 (en) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology Poly (amino acid) targeting moieties
DE102007017654A1 (en) 2007-04-12 2008-10-16 Henkel Ag & Co. Kgaa Bis (hydroxyquinoline) metal complexes as bleaching catalysts
CN101317847B (en) 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 Medicament composition for eyes or nose, and uses thereof
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
AR067027A1 (en) 2007-06-19 2009-09-30 Astrazeneca Ab DERIVATIVES OF 2, 3-DIHIDRO-1H-PIRROL [3, 4B] QUINOLIN-1-ONA, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDITATED BY THE MODULATION OF THE ACTIVITY OF RECEIVER GABA A.
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8535726B2 (en) 2007-07-27 2013-09-17 The Board Of Trustees Of The Leland Stanford Junior University Supramolecular functionalization of graphitic nanoparticles for drug delivery
CN101108846B (en) 2007-08-10 2011-02-09 东南大学 4- fragrant amido quinazoline derivatives and method of manufacturing the same and application in pharmacy thereof
US20090062337A1 (en) 2007-08-31 2009-03-05 Wysis Technology Foundation, Inc. Treatment of Microbial Infections
DE102008012435A1 (en) 2008-02-29 2009-09-03 Schebo Biotech Ag New quinazoline compounds are tyrosin-kinase inhibitors e.g. to treat cancer, hematologic or solid tumors, non-Hodgkin tumors or T-cell lymphoma; and for the modulation of the cell cycle, cell differentiation, apoptosis or angiogenesis
WO2009030224A2 (en) 2007-09-07 2009-03-12 Schebo Biotech Ag Novel quinazoline compounds and the use thereof for treating cancerous diseases
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
US20110306572A1 (en) 2007-09-24 2011-12-15 Tragara Pharmaceuticals, Inc COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]
ATE554076T1 (en) 2008-01-17 2012-05-15 Bayer Pharma AG SULFOXIMINE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE MODULATORS, THEIR PRODUCTION AND THEIR USE AS MEDICATIONS
WO2009094211A1 (en) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Quinazoline compounds and methods of treating cancer
EP2255201B1 (en) 2008-02-28 2014-08-06 Life Technologies Corporation Fluorescence polarization herg assay
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
MX2010012290A (en) 2008-05-14 2011-02-21 Amgen Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer.
EP2149565A1 (en) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfoximine substituted chinazoline derivatives as immune modulators for the treatment of inflammatory and allergic diseases
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
TWI580441B (en) 2008-09-19 2017-05-01 愛爾康研究有限公司 Stabilized pharmaceutical sub-micron suspensions and methods of forming same
EP2532657B9 (en) 2008-10-14 2017-04-19 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
WO2010056758A1 (en) 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
CN101747306B (en) 2008-11-28 2012-08-29 中国中化股份有限公司 Substituent ether compound and application thereof
JP5471063B2 (en) 2009-02-23 2014-04-16 住友化学株式会社 Cyclic compound, metal complex and modified metal complex thereof
TWI461197B (en) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
AU2010226829A1 (en) 2009-03-18 2011-09-15 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
WO2010151784A2 (en) 2009-06-26 2010-12-29 The General Hospital Corporation Antimicrobial compounds
CA2780111A1 (en) 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
DE102010006121B4 (en) 2010-01-29 2022-08-11 Merck Patent Gmbh Materials for organic electroluminescent devices
DE102010007938A1 (en) 2010-02-12 2011-10-06 Merck Patent Gmbh Electroluminescent polymers, process for their preparation and their use
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
JP5654246B2 (en) 2010-03-03 2015-01-14 一般社団法人ファルマバレープロジェクト支援機構 Pharmaceutical composition comprising a quinazoline compound as an active ingredient
TWI516264B (en) 2010-05-06 2016-01-11 臺北醫學大學 Aroylquinoline compounds
DE102010023949A1 (en) 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ lecithin microemulsion gel formulation
WO2011159328A1 (en) 2010-06-16 2011-12-22 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
US20120252756A1 (en) 2010-06-25 2012-10-04 Coffey Martin J Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye
US8791113B2 (en) 2010-06-28 2014-07-29 Merck Patent Gmbh 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
EP2595613B1 (en) 2010-07-22 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for use in a method of preventing or treating viral infection
WO2012013884A1 (en) 2010-07-29 2012-02-02 Laboratoires Fournier Sa Compounds for the treatment/prevention of ocular inflammatory diseases
JP2013537533A (en) 2010-07-30 2013-10-03 ランバクシー ラボラトリーズ リミテッド Matrix metalloproteinase inhibitor
WO2012025237A1 (en) 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012040499A2 (en) 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
CA2812361A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
SG188642A1 (en) 2010-09-24 2013-05-31 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
JP2013538821A (en) 2010-09-24 2013-10-17 ランバクシー ラボラトリーズ リミテッド Matrix metalloproteinase inhibitor
CN103347520A (en) 2010-10-13 2013-10-09 波士顿大学管理委员会 Inhibitor of late SV40 factor (LSF) as cancer chemotherapeutics
WO2012054923A2 (en) 2010-10-22 2012-04-26 Bind Biosciences, Inc. Therapeutic nanoparticles with high molecular weight copolymers
US20120121718A1 (en) 2010-11-05 2012-05-17 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
DE102010050570A1 (en) 2010-11-05 2012-05-10 F. Holzer Gmbh Composition and medicaments containing ω-3 fatty acids and an inhibitor of NF-κB transcription factor
WO2012064898A1 (en) 2010-11-09 2012-05-18 Yuan Chen Singleton inhibitors of sumoylation enzymes and methods for their use
WO2012071042A1 (en) 2010-11-24 2012-05-31 Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services Compositions and methods for treating or preventing lupus
WO2012074980A2 (en) 2010-12-01 2012-06-07 Dara Biosciences, Inc. Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
AR084433A1 (en) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
US20140024627A1 (en) 2011-01-03 2014-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
US11179500B2 (en) 2011-02-24 2021-11-23 Emory University JAB1 inhibitory compositions for ossification and methods related thereto
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2012135416A1 (en) 2011-03-29 2012-10-04 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
AU2012242807A1 (en) 2011-04-14 2013-11-07 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8507686B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
CN103781766A (en) 2011-04-18 2014-05-07 阿勒根公司 Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
US20140056889A1 (en) 2011-04-26 2014-02-27 Genentech, Inc. Compositions and method for treating autoimmune diseases
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
BR112013028735A2 (en) 2011-05-12 2017-12-05 Foresight Biotherapeutics Inc stable povidone iodine compositions with steroids or non-steroidal anti-inflammatory drugs
WO2012158435A1 (en) 2011-05-17 2012-11-22 Han-Jie Zhou Compositions and methods for jamm protein inhibition
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
MX2013015204A (en) 2011-06-29 2014-02-17 Otsuka Pharma Co Ltd Quinazolines as therapeutic compounds and related methods of use.
WO2013013614A1 (en) 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof
JP5753027B2 (en) 2011-08-22 2015-07-22 ユー・ディー・シー アイルランド リミテッド ORGANIC ELECTROLUMINESCENT ELEMENT, COMPOUND, AND LIGHT EMITTING DEVICE, DISPLAY DEVICE AND LIGHTING DEVICE USING THE ELEMENT
TW201325601A (en) 2011-09-16 2013-07-01 Foresight Biotherapeutics Inc Stable povidone-iodine compositions
WO2013061269A1 (en) 2011-10-26 2013-05-02 Micro Labs Limited Combinations of loteprednol and olopatadine for the treatment of ocular allergies
AU2012332176B2 (en) 2011-11-03 2016-03-10 Tlc Biopharmaceuticals, Inc. Pharmaceutical compositions of hydrophobic camptothecin derivatives
WO2013065028A1 (en) 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
US20130116279A1 (en) 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
US9458131B2 (en) 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
CN103102345B (en) 2011-11-14 2015-06-03 广东东阳光药业有限公司 Aminoquinazoline derivative, salts thereof and application method
TWI577671B (en) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN103102342B (en) 2011-11-14 2014-10-29 广东东阳光药业有限公司 Aminoquinazoline derivative, salts thereof and application method
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
CA2859046C (en) 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
CN103183674B (en) 2011-12-31 2017-09-12 江苏先声药业有限公司 One class fused heterocyclic derivative and its application
AR089939A1 (en) 2012-02-09 2014-10-01 Glenmark Pharmaceuticals Sa BICYCLE COMPOUNDS AS INHIBITORS OF mPGES-1
US9458185B2 (en) 2012-02-10 2016-10-04 The Regents Of The University Of California First row metal-based catalysts for hydosilylation
CN103304572A (en) 2012-03-09 2013-09-18 上海医药集团股份有限公司 3-cyanoquinoline compound as well as pharmaceutical composition and application thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP2854818A4 (en) 2012-06-01 2016-04-06 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
EP2861588A4 (en) 2012-06-15 2016-04-20 Univ California Novel therapeutics for brain cancer
CA2879789C (en) 2012-07-20 2019-08-20 Cleave Biosciences, Inc. Fused pyrimidines as inhibitors of p97 complex
CN103804292A (en) 2012-11-05 2014-05-21 江苏唐果医药科技有限公司 HDM2 and HDMX dual inhibitor 3-nitrile quinoline derivative and preparation method and application thereof
US20150259649A1 (en) 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
KR20150080619A (en) 2012-11-08 2015-07-09 아지오스 파마슈티컬스 아이엔씨. Therapeutic compounds and compositions and their use as pkm2 modulators
US9701638B2 (en) 2012-11-09 2017-07-11 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
KR102051910B1 (en) 2012-11-30 2019-12-09 에스에프씨주식회사 Deuteriated organometallic complex and organic light-emitting diode including the same
WO2014086284A1 (en) 2012-12-04 2014-06-12 上海医药集团股份有限公司 Deuterated 3-cyano quinoline compound, pharmaceutical composition, preparation method and use thereof
JP6556630B2 (en) 2012-12-21 2019-08-07 メルク パテント ゲーエムベーハー Metal complex
KR102084421B1 (en) 2013-02-15 2020-03-05 에스에프씨주식회사 Novel organic compounds for organic light-emitting diode and organic light-emitting diode including the same
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) * 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR102118013B1 (en) 2013-02-22 2020-06-05 에스에프씨주식회사 Novel organic compounds for organic light-emitting diode and organic light-emitting diode including the same
EP2964625B1 (en) 2013-03-04 2018-07-25 Health Sciences North Research Institute Quinoline sulfonyl derivatives and uses thereof
WO2014141057A2 (en) 2013-03-12 2014-09-18 Mahesh Kandula Compositions and methods for the treatment of cancer
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
MX367420B (en) 2013-03-14 2019-08-21 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins.
AU2014233757B2 (en) 2013-03-18 2017-12-21 Genoscience Pharma Quinolines derivatives as novel anticancer agents
WO2014182954A1 (en) 2013-05-08 2014-11-13 Colorado Seminary, Which Owns And Operates The University Of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
EP2996691A1 (en) 2013-05-16 2016-03-23 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for inhibiting drug-resistant strains of hiv-1 integrase
WO2014111269A2 (en) 2013-10-14 2014-07-24 Merck Patent Gmbh Materials for electronic devices
MX355330B (en) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336767B2 (en) * 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10626121B2 (en) * 2016-09-08 2020-04-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US11104685B2 (en) * 2016-09-08 2021-08-31 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
McMahon et al (2000) *
Pinedo et al (2000) *

Also Published As

Publication number Publication date
CN109688818A (en) 2019-04-26
AU2017324251A1 (en) 2019-03-21
WO2018048746A1 (en) 2018-03-15
US20210355136A1 (en) 2021-11-18
CA3036065A1 (en) 2018-03-15
JP2019533641A (en) 2019-11-21
AU2020217446A1 (en) 2020-09-03
BR112019004463A2 (en) 2019-05-28
EP3509421A1 (en) 2019-07-17
AU2020217446B2 (en) 2022-05-26
US20190270752A1 (en) 2019-09-05
US10336767B2 (en) 2019-07-02
US10626121B2 (en) 2020-04-21
EP3509421A4 (en) 2020-05-20
KR20190051010A (en) 2019-05-14
US11104685B2 (en) 2021-08-31
US20200216460A1 (en) 2020-07-09
US20180065977A1 (en) 2018-03-08
MX2019002629A (en) 2019-10-07

Similar Documents

Publication Publication Date Title
US20220106326A1 (en) Crystalline forms of therapeutic compounds and uses thereof
US10766907B2 (en) Crystalline forms of therapeutic compounds and uses thereof
US11021487B2 (en) Crystalline forms of therapeutic compounds and uses thereof
US20240058265A1 (en) Treatment of ocular diseases using endothelin receptor antagonists
US10875857B2 (en) 1-amino-triazolo(1,5-A)pyridine-substituted urea derivative and uses thereof
US10253045B2 (en) Crystalline forms of a therapeutic compound and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: KALA PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NGUYEN, MINH NGOC;ONG, WINSTON ZAPANTA;REEL/FRAME:058417/0913

Effective date: 20160920

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION